Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKGP.L Regulatory News (KGP)

  • There is currently no data for KGP

Interim Management Statement

10 Nov 2014 07:00

RNS Number : 5259W
Kingspan Group PLC
10 November 2014
ย 

Kingspan Group Plc

Interim Management Statement

ย 

10 November 2014

ย 

Kingspan Group plc, the global leader in high performance insulation and building envelopes, today issues the following Interim Management Statement, with trading information for the period from 1 July to 30 September 2014.

ย 

Sales in the nine month period to 30 September were โ‚ฌ1.39bn, up 5% on the prior year (+5% constant currency). A solid sales performance was also recorded in the third quarter with revenue up 7% (+5% constant currency) compared to the same period in 2013.

Insulated Panels revenue in the first nine months increased by 9% (+9% constant currency), and by 8% (+7% constant currency) in the third quarter. The UK continued to perform well with encouraging activity across most building segments. After a sluggish second quarter sales performance, Mainland Europe remained weak through the third quarter reflecting somewhat of an abatement in German market activity. The pace of sales growth in North America improved in the third quarter helped by a strong order book as we entered the second half. Order intake also showed a significant improvement over prior year. Activity in Australasia continued the strong trend evident in the first half.

Insulation Board revenue in the first nine months was up 3% (+1% constant currency) compared with the same period last year, and ahead by 6% in quarter three (+2% constant currency). The UK sales performance was positive through the third quarter, and Mainland European sales were relatively stable overall year on year. Further progress in market conversion was evident in Australia during the third quarter.

Environmental revenue in the first nine months was ahead of last year by 1% (-2% constant currency) and by 3% (-3% constant currency) in the third quarter, continuing on the path of relative stabilisation seen earlier in the year.

Access Floors revenue in the first nine months was 4% behind the same period last year (-4% constant currency). Sales in the third quarter were ahead by 11% (+8% constant currency) with continuing momentum evident in UK office construction activity and an improvement in the US relative to a weak first half.

ย Net debt at the end of September 2014 was โ‚ฌ107.7m, โ‚ฌ39.1m lower than at the same point in 2013. The fourth quarter is a seasonally cash generative period and this would indicate net debt levels by year end in the region of โ‚ฌ140m after taking account of the acquisitions of Pactiv Insulation (North America) and PAL (UAE). These insulation board businesses were separately acquired in October for a combined consideration of โ‚ฌ77m.The relative optimism that prevailed earlier in the year appears to have waned in recent months, particularly in Europe. Whilst our business continues to perform solidly, we nonetheless are mindful of what are currently more tempered 2015 economic forecasts, and remain focused on driving the Kingspan proposition, whatever the macro climate.

The fourth quarter of 2013 was particularly strong for the Group. Notwithstanding that, and with this seasonally important and often variable period to come, we expect to deliver a full-year trading profit in the region of โ‚ฌ144m (+17% versus 2013).

ย 

For further information contact:

ย 

Gene Murtagh, Chief Executive Officer Tel: +353 (0) 42 9698000

ย 

Geoff Doherty, Chief Financial Officer Tel: +353 (0) 42 9698000

ย 

Douglas Keatinge, Murray Consultants Tel: +353 (0) 1 4980300

ย 

ย 

ย 

This information is provided by RNS
The company news service from the London Stock Exchange
ย 
END
ย 
ย 
IMSBRBDBGUGBGSR
Date   Source Headline
13th Dec 20226:12 pmRNSHolding(s) in Company
1st Dec 20224:45 pmRNSTotal Voting Rights
29th Nov 20222:25 pmRNSHolding(s) in Company
24th Nov 20221:13 pmRNSHolding(s) in Company
9th Nov 20223:50 pmRNSDirector/PDMR Shareholding
8th Nov 20229:25 amRNSHolding(s) in Company
7th Nov 20227:00 amRNSTrading Statement
1st Nov 20221:40 pmRNSTotal Voting Rights
27th Oct 20227:00 amRNSHolding(s) in Company
21st Oct 20223:29 pmRNSHolding(s) in Company
3rd Oct 20225:39 pmRNSDirector/PDMR Shareholding
3rd Oct 20223:07 pmRNSHolding(s) in Company
3rd Oct 20221:00 pmRNSTotal Voting Rights
28th Sep 20224:04 pmRNSHolding(s) in Company
27th Sep 20225:19 pmRNSHolding(s) in Company
27th Sep 20229:27 amRNSAcquisition
16th Sep 20224:23 pmRNSHolding(s) in Company
14th Sep 202212:35 pmRNSHolding(s) in Company
14th Sep 20229:29 amRNSHolding(s) in Company
1st Sep 20221:01 pmRNSTotal Voting Rights
25th Aug 202212:00 pmRNSDirector Declaration
23rd Aug 20223:09 pmRNSDirector/PDMR Shareholding
19th Aug 20224:35 pmRNSPrice Monitoring Extension
19th Aug 20227:05 amRNSDirectorate Change
19th Aug 20227:00 amRNSHalf-year Report
17th Aug 202211:42 amRNSHolding(s) in Company
17th Aug 202211:26 amRNSHolding(s) in Company
11th Aug 20225:07 pmRNSHolding(s) in Company
1st Jul 20229:36 amRNSHolding(s) in Company
1st Jul 20229:30 amRNSBlock listing Interim Review
1st Jul 20229:00 amRNSTotal Voting Rights
27th Jun 20225:59 pmRNSHolding(s) in Company
22nd Jun 20223:47 pmRNSHolding(s) in Company
20th Jun 20227:00 amRNSPre-Close Statement
7th Jun 202212:09 pmRNSDirector/PDMR Shareholding
1st Jun 20223:48 pmRNSTotal Voting Rights
18th May 20223:04 pmRNSDirector/PDMR Shareholding
6th May 20224:58 pmRNSDirector/PDMR Shareholding
3rd May 202211:52 amRNSTotal Voting Rights
29th Apr 20223:26 pmRNSResult of AGM
29th Apr 20227:00 amRNSTrading Statement
27th Apr 20226:22 pmRNSHolding(s) in Company
20th Apr 20225:38 pmRNSHolding(s) in Company
14th Apr 20224:47 pmRNSHolding(s) in Company
14th Apr 20227:00 amRNSHolding(s) in Company
13th Apr 20229:31 amRNSHolding(s) in Company
11th Apr 20225:44 pmRNSHolding(s) in Company
11th Apr 202212:37 pmRNSPlanet Passionate Call 2022
11th Apr 20227:00 amRNSHolding(s) in Company
7th Apr 20225:53 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.